FindTrial
Sign In

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00348062
Enrollment
Unknown
Registered
2006-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2007-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Brief summary

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Interventions

DRUGBimatoprost

Sponsors

Innovative Medical
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* · Male or female \> 18 years of age * No prior use of bimatoprost * Diagnosis of open-angle glaucoma or ocular hypertension * Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

* · Known contraindication to bimatoprost * Uncontrolled systemic disease * Active ocular disease other than glaucoma or ocular hypertension * Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted) * History of intraocular surgery within the last 3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026